Holger built his career on the two pillars of strategy consulting and commercialization of innovations in the pharmaceutical industry. After his forming education at Bain & Company, Holger joined Novartis Pharma in headquarter- and country-organization roles, covering the entire lifecycle of a pharmaceutical drug from first-in-man trials to loss-of-exclusivity transitions. Following his career at Novartis, Holger ventured into the world of start-ups, where he held commercial leadership positions at the cell therapy company Athenex, the CRO Biognosys, and the medical device start-up Spiden.
Today, Holger works as an independent advisor to innovative pharmaceutical companies and holds non-executive director roles. His core expertise is in positioning- and commercialization of pharmaceutical drugs in the European markets, where he is agnostic to the therapeutic area.
Umbrex independent consultants are available where you need them – in all major markets and every global region.